Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG, Flandre P, Molina JM, Katlama C, Yeni P, Raffi F, Antoun Z, Ait-Khaled M, Calvez V. Marcelin AG, et al. Antimicrob Agents Chemother. 2008 Dec;52(12):4251-7. doi: 10.1128/AAC.00514-08. Epub 2008 Oct 13. Antimicrob Agents Chemother. 2008. PMID: 18852278 Free PMC article. Clinical Trial.
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
Soulié C, Assoumou L, Ghosn J, Duvivier C, Peytavin G, Ait-Arkoub Z, Molina JM, Costagliola D, Katlama C, Calvez V, Marcelin AG. Soulié C, et al. Among authors: marcelin ag. AIDS. 2009 Jul 31;23(12):1605-8. doi: 10.1097/QAD.0b013e32832d9031. AIDS. 2009. PMID: 19487903 Clinical Trial.
Raltegravir as functional monotherapy leads to virological failure and drug resistance in highly treatment-experienced HIV-infected patients.
Caby F, Valin N, Marcelin AG, Schneider L, Andrade R, Guiguet M, Tubiana R, Canestri A, Valantin MA, Peytavin G, Pacanowski J, Morand-Joubert L, Calvez V, Girard PM, Katlama C. Caby F, et al. Among authors: marcelin ag. Scand J Infect Dis. 2010 Jul;42(6-7):527-32. doi: 10.3109/00365541003621502. Scand J Infect Dis. 2010. PMID: 20222846
Risk factors for raltegravir resistance development in clinical practice.
Malet I, Fourati S, Morand-Joubert L, Flandre P, Wirden M, Haim-Boukobza S, Sayon S, Pattery T, Simon A, Katlama C, Girard PM, Calvez V, Marcelin AG. Malet I, et al. Among authors: marcelin ag. J Antimicrob Chemother. 2012 Oct;67(10):2494-500. doi: 10.1093/jac/dks254. Epub 2012 Jul 4. J Antimicrob Chemother. 2012. PMID: 22763565
467 results